Inflammation is widely acknowledged as a significant characteristic of cancer, playing a substantial function in both the initiation and advancement of cancers. In this research, we planned to compare pan-immune inflammation markers and other well-known markers (systemic immune inflammation index and neutrophil to lymphocyte ratio) to predict prognosis in individuals treated with radical cystectomy for bladder cancer. Methods: In this retrospective analysis, we focused on preoperative PIV, systemic immune inflammation index (SII), and neutrophil–lymphocyte ratio (NLR) in 193 individuals managed with radical cystectomy for bladder cancer between January 2016 and November 2022. Multivariable logistic regression assessments were performed to assess the predictive capabilities of PIV, SII, and NLR for infiltration of lymph nodes (N), aggressive tumor stage (pT3/pT4), and any non-organ limited disease at the time of RC. Multivariable Cox regression analyses were conducted to assess the predictive impact of PIV on Relapse-free survival (RFS), Cancer-specific survival (CSS), and Overall survival (OS). Results: Our individuals were divided into high PIV and low PIV cohorts using the optimal cut-off value (340.96 × 109/L) based on receiver operating characteristic curve analysis for relapse-free survival. In multivariable preoperative logistic regression models, only SII and PIV correlated with the infiltration of lymph nodes, aggressive disease, and any non-organ confined disease. In multivariable Cox regression models considering presurgical clinicopathological variables, a higher PIV was associated with diminished RFS (p= 0.017) and OS (p= 0.029). In addition, in multivariable Cox regression models for postoperative outcomes, a high PIV correlated with both RFS (p= 0.034) and OS (p= 0.048). Conclusions: Our study suggests that PIV and SII are two very similar markers that may serve as independent and significant predictors of aggressive disease and worse survival impacts on individuals undergoing radical cystectomy for bladder neoplasm.
炎症被广泛认为是癌症的一个重要特征，在癌症的发生和发展过程中起着重要作用。本研究旨在比较泛免疫炎症标志物与其他已知标志物（系统免疫炎症指数和中性粒细胞与淋巴细胞比值），以预测接受根治性膀胱切除术的膀胱癌患者的预后。方法：在这项回顾性分析中，我们重点关注了2016年1月至2022年11月期间接受根治性膀胱切除术治疗的193例膀胱癌患者的术前泛免疫炎症值、系统免疫炎症指数和中性粒细胞与淋巴细胞比值。采用多变量逻辑回归分析评估泛免疫炎症值、系统免疫炎症指数和中性粒细胞与淋巴细胞比值对淋巴结浸润、侵袭性肿瘤分期以及根治性膀胱切除术时任何非器官局限性疾病的预测能力。通过多变量Cox回归分析评估泛免疫炎症值对无复发生存期、癌症特异性生存期和总生存期的预测影响。结果：根据无复发生存期的受试者工作特征曲线分析确定最佳截断值（340.96×10⁹/L），将患者分为高泛免疫炎症值组和低泛免疫炎症值组。在多变量术前逻辑回归模型中，仅系统免疫炎症指数和泛免疫炎症值与淋巴结浸润、侵袭性疾病及任何非器官局限性疾病相关。在考虑术前临床病理学变量的多变量Cox回归模型中，较高的泛免疫炎症值与较差的无复发生存期和总生存期相关。此外，在术后结果的多变量Cox回归模型中，高泛免疫炎症值与较差的无复发生存期和总生存期均相关。结论：我们的研究表明，泛免疫炎症值和系统免疫炎症指数是两个非常相似的标志物，可作为接受根治性膀胱切除术的膀胱癌患者侵袭性疾病和较差生存影响的独立且重要的预测指标。
肿瘤(癌症)患者之家